HRP20200607T1 - Rsv-specifična protutijela i njihovi funkcionalni dijelovi - Google Patents
Rsv-specifična protutijela i njihovi funkcionalni dijelovi Download PDFInfo
- Publication number
- HRP20200607T1 HRP20200607T1 HRP20200607TT HRP20200607T HRP20200607T1 HR P20200607 T1 HRP20200607 T1 HR P20200607T1 HR P20200607T T HRP20200607T T HR P20200607TT HR P20200607 T HRP20200607 T HR P20200607T HR P20200607 T1 HRP20200607 T1 HR P20200607T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antigen
- chain variable
- antibody
- variable region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (5)
1. Protutijelo ili njegov ulomak koji veže antigen, pri čemu protutijelo ili njegov ulomak koji veže antigen specifično veže respiratorni sincicijski virus (RSV) i učinkovito je u neutralizaciji oba soja A i B podtipa RSV i sadrži:
varijabilnu regiju teškog lanca koja je najmanje 98% identična sa SEQ ID NO: 15 i varijabilnu regiju lakog lanca koja je identična sa SEQ ID NO: 8,
pri čemu CDR1 sekvenca varijabilne regije teškog lanca sadrži DYIIN (SEQ ID NO: 9), CDR2 sekvenca varijabilne regije teškog lanca sadrži GIIPVLGTVHYGPKFQG (SEQ ID NO: 10), i CDR3 sekvenca varijabilne regije teškog lanca sadrži sekvencu koja je identična sa, ili se razlikuje za jednu ili dvije aminokiseline od ETALVVSTTILPHYFDN (SEQ ID NO:3) ili ETALVVSTTYRPHYFDN (SEQ ID NO: 11), i
pri čemu varijabilna regija teškog lanca nadalje sadrži sljedeće aminokiseline koje se razlikuju od SEQ ID NO: 7:
Pozicija u odnosu na SEQ ID NO: 7 Aminokiselina
30 E
31 D
37 V
61 G
81 M
82 E
84 S
2. Protutijelo ili ulomak koji veže antigen prema patentnom zahtjevu 1, naznačeno time što sadrži varijabilnu regiju teškog lanca koja je najmanje 99% identična SEQ ID NO: 15.
3. Protutijelo ili ulomak koji veže antigen prema patentnom zahtjevu 1 naznačeno time što protutijelo ili njegov ulomak koji veže antigen sadrži humani IgG1 izotip i sadrži Fc regiju koja sadrži Y na poziciji 252, T na poziciji 254, i E na poziciji 256, pri čemu brojanje odgovara EU indeksu u Kabatu.
4. Ulomak koji veže antigen prema patentnom zahtjevu 1, naznačen time što je njegov ulomak koji veže antigen jednolančano protutijelo, jednolančani varijabilni ulomak (scFv), Fab ulomak, ili F(ab')2 ulomak.
5. Protutijelo ili njegov ulomak koji veže antigen prema bilo kojem od prethodnih zahtjeva naznačeno time što se koristi u postupku prevencije ili liječenja RSV infekcije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461927819P | 2014-01-15 | 2014-01-15 | |
| PCT/US2015/011391 WO2015108967A2 (en) | 2014-01-15 | 2015-01-14 | Rsv-specific antibodies and functional parts thereof |
| EP15737068.5A EP3094353B1 (en) | 2014-01-15 | 2015-01-14 | Rsv-specific antibodies and functional parts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200607T1 true HRP20200607T1 (hr) | 2020-07-10 |
Family
ID=53543612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200607TT HRP20200607T1 (hr) | 2014-01-15 | 2015-01-14 | Rsv-specifična protutijela i njihovi funkcionalni dijelovi |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US20160340414A1 (hr) |
| EP (3) | EP3741390A1 (hr) |
| JP (4) | JP6836398B2 (hr) |
| KR (1) | KR102188437B1 (hr) |
| CN (2) | CN116355080A (hr) |
| AU (4) | AU2015206570A1 (hr) |
| CA (1) | CA2933200A1 (hr) |
| CY (2) | CY1123425T1 (hr) |
| DK (1) | DK3094353T3 (hr) |
| ES (1) | ES2795727T3 (hr) |
| FI (1) | FIC20230016I1 (hr) |
| FR (1) | FR23C1016I1 (hr) |
| HR (1) | HRP20200607T1 (hr) |
| HU (2) | HUE048855T2 (hr) |
| LT (2) | LT3094353T (hr) |
| MX (1) | MX374517B (hr) |
| NL (1) | NL301228I2 (hr) |
| NO (1) | NO2023016I1 (hr) |
| PL (1) | PL3094353T3 (hr) |
| PT (1) | PT3094353T (hr) |
| RS (1) | RS60387B1 (hr) |
| SI (1) | SI3094353T1 (hr) |
| SM (1) | SMT202000282T1 (hr) |
| TW (1) | TWI705974B (hr) |
| WO (1) | WO2015108967A2 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| SI3094353T1 (sl) | 2014-01-15 | 2020-07-31 | Medimmune, Llc | RSY-specifična protitelesa in njihovi funkcionalni deli |
| US11479600B2 (en) | 2016-10-21 | 2022-10-25 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| TW202228779A (zh) * | 2017-03-01 | 2022-08-01 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| WO2019152600A1 (en) * | 2018-01-31 | 2019-08-08 | The Wistar Institute Of Anatomy And Biology | Nucleic acid antibody constructs for use against respiratory syncytial virus |
| CN111606993B (zh) * | 2019-02-26 | 2022-06-28 | 中国科学院上海生命科学研究院 | 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用 |
| US12024553B2 (en) | 2019-04-30 | 2024-07-02 | Medimmune Limited | Dosage regimens for and compositions including anti-RSV antibodies |
| EP4402166A2 (en) | 2021-09-13 | 2024-07-24 | MedImmune Limited | Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab |
| CN119264248A (zh) * | 2022-07-22 | 2025-01-07 | 北京智仁美博生物科技有限公司 | 抗呼吸道合胞病毒中和性抗体及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| CA2585891A1 (en) * | 2004-10-29 | 2006-05-11 | Medimmune, Inc. | Methods of preventing and treating rsv infections and related conditions |
| CA2587766A1 (en) * | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| ES2625798T3 (es) | 2006-10-02 | 2017-07-20 | E. R. Squibb & Sons, L.L.C. | Anticuerpos humanos que se unen a CXCR4 y usos de los mismos |
| JP2010534057A (ja) * | 2007-03-06 | 2010-11-04 | シムフォゲン・アクティーゼルスカブ | 呼吸器合胞体ウイルス感染症を治療するための組換え抗体 |
| EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| KR20100049568A (ko) * | 2007-06-26 | 2010-05-12 | 메디뮨 엘엘씨 | Ｒｓｖ 감염 및 관련 병증의 치료 방법 |
| US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| BRPI0906490A2 (pt) | 2008-01-15 | 2015-07-14 | Abbott Lab | Vetores de expressão de mamífero melhorados e uso dos mesmos |
| AU2010271583B2 (en) * | 2009-07-15 | 2015-02-12 | Kling Biotherapeutics B.V. | Means and methods for producing high affinity antibodies |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| KR101789343B1 (ko) * | 2009-10-06 | 2017-10-23 | 메드임뮨 리미티드 | Ｒｓｖ-특이적 결합 분자 |
| WO2011056697A1 (en) * | 2009-10-28 | 2011-05-12 | Medimmune, Llc | Topical methods of treating rsv infections and related conditions |
| JP6200437B2 (ja) * | 2012-03-16 | 2017-09-20 | ユニバーシティ ヘルス ネットワーク | Ｔｏｓｏ活性を調節するための方法および組成物 |
| WO2013177264A1 (en) * | 2012-05-22 | 2013-11-28 | Shire Human Genetic Therapies, Inc. | Anti-ccl2 antibodies for treatment of scleroderma |
| DK2950886T3 (da) | 2013-02-01 | 2020-03-23 | Medimmune Llc | Respiratorisk syncytialvirus-f-protein-epitoper |
| SI3094353T1 (sl) | 2014-01-15 | 2020-07-31 | Medimmune, Llc | RSY-specifična protitelesa in njihovi funkcionalni deli |
| TW202228779A (zh) | 2017-03-01 | 2022-08-01 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| JP2020509025A (ja) | 2017-03-01 | 2020-03-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | モノクローナル抗体製剤 |
-
2015
- 2015-01-14 SI SI201531183T patent/SI3094353T1/sl unknown
- 2015-01-14 EP EP20161884.0A patent/EP3741390A1/en not_active Withdrawn
- 2015-01-14 MX MX2016008639A patent/MX374517B/es active IP Right Grant
- 2015-01-14 HU HUE15737068A patent/HUE048855T2/hu unknown
- 2015-01-14 AU AU2015206570A patent/AU2015206570A1/en not_active Abandoned
- 2015-01-14 WO PCT/US2015/011391 patent/WO2015108967A2/en active Application Filing
- 2015-01-14 CN CN202211184987.8A patent/CN116355080A/zh active Pending
- 2015-01-14 RS RS20200640A patent/RS60387B1/sr unknown
- 2015-01-14 JP JP2016541720A patent/JP6836398B2/ja active Active
- 2015-01-14 CA CA2933200A patent/CA2933200A1/en active Pending
- 2015-01-14 PL PL15737068T patent/PL3094353T3/pl unknown
- 2015-01-14 EP EP15737068.5A patent/EP3094353B1/en active Active
- 2015-01-14 HR HRP20200607TT patent/HRP20200607T1/hr unknown
- 2015-01-14 SM SM20200282T patent/SMT202000282T1/it unknown
- 2015-01-14 US US15/111,610 patent/US20160340414A1/en not_active Abandoned
- 2015-01-14 PT PT157370685T patent/PT3094353T/pt unknown
- 2015-01-14 KR KR1020167020393A patent/KR102188437B1/ko active Active
- 2015-01-14 CN CN201580003410.4A patent/CN105916520A/zh active Pending
- 2015-01-14 ES ES15737068T patent/ES2795727T3/es active Active
- 2015-01-14 DK DK15737068.5T patent/DK3094353T3/da active
- 2015-01-14 EP EP23215838.6A patent/EP4353316A3/en active Pending
- 2015-01-14 LT LTEP15737068.5T patent/LT3094353T/lt unknown
- 2015-01-15 TW TW104101373A patent/TWI705974B/zh active
-
2018
- 2018-06-08 US US16/003,455 patent/US10689437B2/en active Active
-
2020
- 2020-02-10 JP JP2020020602A patent/JP2020103293A/ja active Pending
- 2020-05-01 US US16/864,454 patent/US11186628B2/en active Active
- 2020-06-05 CY CY20201100509T patent/CY1123425T1/el unknown
- 2020-06-10 AU AU2020203831A patent/AU2020203831A1/en not_active Abandoned
-
2021
- 2021-06-25 AU AU2021204339A patent/AU2021204339B2/en active Active
- 2021-10-22 US US17/451,955 patent/US11661449B2/en active Active
-
2023
- 2023-01-27 JP JP2023010903A patent/JP2023052693A/ja active Pending
- 2023-04-18 US US18/302,400 patent/US12173050B2/en active Active
- 2023-04-25 NO NO2023016C patent/NO2023016I1/no unknown
- 2023-04-25 FR FR23C1016C patent/FR23C1016I1/fr active Active
- 2023-04-25 CY CY2023011C patent/CY2023011I1/el unknown
- 2023-04-26 FI FIC20230016C patent/FIC20230016I1/fi unknown
- 2023-04-26 NL NL301228C patent/NL301228I2/nl unknown
- 2023-04-28 LT LTPA2023514C patent/LTPA2023514I1/lt unknown
- 2023-05-02 HU HUS2300019C patent/HUS2300019I1/hu unknown
-
2024
- 2024-11-11 US US18/943,007 patent/US20250179153A1/en active Pending
-
2025
- 2025-01-09 JP JP2025003702A patent/JP2025063143A/ja active Pending
- 2025-02-14 AU AU2025201056A patent/AU2025201056A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200607T1 (hr) | Rsv-specifična protutijela i njihovi funkcionalni dijelovi | |
| HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| HRP20210113T1 (hr) | Stabilizirani topljivi prefuzijski rsv f protein za upotrebu u profilaksi rsv infekcije | |
| NZ703035A (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
| HRP20192280T1 (hr) | Anti-ceacam6 protutijela i njihova uporaba | |
| ME02678B (me) | Antitijela na ox-40 i postupci njihove primjene | |
| NZ597996A (en) | Antibodies against human respiratory syncytial virus (rsv) and methods of use | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2018035138A5 (hr) | ||
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| HRP20250602T1 (hr) | Antitijela koja se vežu na sortilin i inhibiraju vezanje progranulina | |
| HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| HRP20200583T1 (hr) | Protutijela koja neutraliziraju gp120 i njihova upotreba | |
| MY186351A (en) | Multispecific antibodies | |
| PE20210377A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| HRP20210892T1 (hr) | Terapijska uporaba specifičnog liganda u bolestima povezanim s msrv | |
| RU2014101707A (ru) | АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
| JP2013198490A5 (hr) |